此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia

2016年12月23日 更新者:Universitaire Ziekenhuizen KU Leuven

Functional dyspepsia (FD) is an extremely common disorder of gastrointestinal function. Recently, impaired duodenal mucosal integrity was reported as a potential pathophysiological mechanism in FD. However, the factors controlling duodenal mucosal integrity remain unknown. In this study, we evaluated whether the luminal bile salt content could play a role in impaired duodenal permeability in FD.

Duodenal biopsies were obtained from 25 healthy volunteers (HV) and 25 FD patients. Biopsies were mounted in Ussing chambers to measure transepithelial resistance (TEER) and paracellular permeability using fluorescein isothiocyanate dextran (FITC-dx4, MW 4kDa). Expression of bile acid-sensing receptors (TGR5, VDR, PXR, FXR and CAR) in duodenal biopsies was measured by western blot and real time RT-PCR. Immunohistochemistry was used to evaluate eosinophil and mastcell infiltration in duodenal biopsies of FD patients and HV. Duodenal fluid aspirates were collected at fixed time points during 1 hour in fasted state and 1.5 hours after a liquid meal (Nutridrink, 200ml). Concentration and composition of the bile salt pool (including glycocholic acid (GC), taurocholic acid (TC), glycochenodeoxycholic acid (GCDC), taurochenodeoxycholic acid (TCDC), glycodeoxycholic acid (GDC), taurodeoxycholic acid (TDC), glycoursodeoxycholic acid (GUDC) and tauroursodeoxycholic acid (TUDC)) in these aspirates was evaluated by liquid chromatography-mass spectrometry-selected ion monitoring analysis (LC-MS/MS).

研究概览

详细说明

The Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms thought to originate in the gastroduodenal region, in the absence of any organic, systemic or metabolic disease that readily explains the complaints. FD is extremely common, affecting up to 15-20% of the population and is associated with significantly decreased quality of life and substantial healthcare costs. The available treatment options for FD are of limited effectiveness, which reflects the poorly understood pathogenesis. Studies indicate that FD is a heterogeneous disorder, in which different pathophysiological mechanisms underlie specific symptom patterns. Traditionally, gastric abnormalities such as impaired accommodation, delayed emptying and hypersensitivity have been believed to be involved in the pathophysiology of FD. More recent studies have suggested that also a number of duodenal abnormalities can be responsible for the generation of symptoms, like increased sensitivity to duodenal acid, increased sensitivity to duodenal lipids and low-grade mucosal inflammation.

The investigators recently showed that FD patients display impaired duodenal mucosal integrity. The trigger of increased permeability is unknown, but it is possible that increased exposure to duodenal bile acids or an altered composition of bile acids leads to impairment of the intestinal barrier. This sustained enhancement of paracellular permeability could facilitate the constant passage of luminal antigens through the mucosa and lead to local mucosal immune responses that manifest as inflammation and finally result in generation of dyspeptic symptoms.

The investigators hypothesized that increased duodenal bile acid exposure or a change in the composition of bile acids lead to impaired duodenal mucosal integrity in FD, allowing luminal substances to pass through the mucosa and result in immune responses and finally in dyspeptic symptom generation. The general aim of this project is to assess if FD patients display increased endogenous duodenal bile acid exposure and a different bile acid composition. In addition, it will be tested whether duodenal mucosal permeability of FD patients with an endogenous duodenal bile acid exposure above the normal range and an altered bile acid composition is higher than in FD patients with a normal endogenous duodenal acid exposure and composition.

Participants will be expected on the department endoscopy of the UZ Gasthuisberg after they have fasted overnight. Before the study, they are asked to fill in a bundle of questionnaires concerning physical complaints, depression, anxiety (disturbances), pain/disease, body/interoceptive awareness, trauma/abuse and personality.

Gastroduodenoscopy will be performed by an experienced endoscopist (Jan Tack). Hereby, 12 duodenal biopsies (2 biopsies at a time) (Radial Jaw™3 with needle; outside diameter 2.2mm; Boston Scientific, 302 Parkway, Global Park, Heredia, Costa Rica) will be obtained. To measure the in vitro transepithelial resistance, 4 biopsies will be examined using an adapted mini-Ussing chambers system. After equilibration, the mucosal side of the tissue will be exposed to 4kDa FITC-dextran as a measure of paracellular permeability. A sample will be taken from the serosal side during 2h at 30min interval. The concentration of fluorescein will then be measured using a fluorescence plate reader. Also, 2 biopsies will be used for mRNA extraction and subsequent cDNA synthesis. This cDNA will be used to measure the gene expression of cell-to-cell adhesion proteins and acid-sensing receptors by means of real-time PCR. In addition, 2 biopsies will be prepared for immunofluorescence and immunohistochemistry and 2 will be used for western blot to measure changes in distribution/expression of the cell-to-cell adhesion proteins and of bile acid-sensitive receptors. Two biopsies will be obtained to study ultrastructural alterations by transmission electron microscopy.

After recovery, a catheter will be introduced in the second duodenum via the nose and the position of the catheter will be checked fluoroscopically. This catheter allows collection of intestinal fluids by means of a syringe to collect duodenal fluid aspirates and characterization of the bile acid composition of those samples (8). After 30 minutes, the participants will be given a specified amount of water (250 mL) (fasted state) and another 30 minutes later a nutritional drink (fed state). Intestinal fluids will be sampled every 15 min for a period of 1 h before the liquid meal intake and until 90 minutes after the liquid meal intake. So, after the total collection period, 7 fractions for the fed state and 4 fractions for the fasted state will be obtained per participant in a time frame of 2 hours and a half. The composition of bile acids of the intestinal samples will be determined by GC-MS-selected ion monitoring analysis.

研究类型

介入性

注册 (实际的)

50

阶段

  • 不适用

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • FD patients have to fulfill the Rome III criteria for functional dyspepsia.

Exclusion Criteria:

  • Symptoms or history of gastrointestinal disease (for healthy volunteers)
  • First degree relatives with celiac disease
  • Diabetes mellitus
  • Allergy/atopy (eczema, asthma, allergic rhinoconjunctivitis)
  • Coagulation disorders/anticoagulant therapy
  • First degree relatives with Crohn's disease or type I diabetes mellitus
  • Intake of antihistamines, ketotifen, cromoglycate, acetylsalicylates, NSAIDs, anticholinergics, theophylline, β2-agonists, codeine or opioid derivatives for at least 2 weeks prior to the study.
  • Steroid or immunosuppressive drug intake any time in the last 6 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Duodenal fluid aspiration
Catheter goes through the mouth in the duodenum to take duodenal biopsies.
Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
Liquid meal of 200 ml.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Duodenal mucosal transepithelial electrical resistance (Ohm*cm^2)
大体时间:2 hours
Measurement for mucosal integrity
2 hours
Duodenal paracellular passage of Fitc Dextran 4 kDa (pmol)
大体时间:2 hours
Measurement for mucosal integrity
2 hours
Glycocholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Taurocholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Glycochenodeoxycholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Taurochenodeoxycholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Glycodeoxycholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Taurodeoxycholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Glycoursodeoxycholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours
Tauroursodeoxycholic acid concentration (mM)
大体时间:2.5 hours
Bile salt
2.5 hours

次要结果测量

结果测量
措施说明
大体时间
Duodenal mucosal mastcell count (number of mastcells/mm^2 lamina propria)
大体时间:2 years
2 years
Duodenal mucosal eosinophil count (number of eosinophils/mm^2 lamina propria)
大体时间:2 years
2 years
RNA expression of Vitamin D receptor (VDR)
大体时间:2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor FXR
大体时间:2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor PXR
大体时间:2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor TGR5
大体时间:2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor CAR
大体时间:2 years
Real-time RT-PCR
2 years
Protein expression of bile acid receptor VDR
大体时间:2 years
Western blot
2 years
Protein expression of bile acid receptor FXR
大体时间:2 years
Western blot
2 years
Protein expression of bile acid receptor PXR
大体时间:2 years
Western blot
2 years
Protein expression of bile acid receptor TGR5
大体时间:2 years
Western blot
2 years
Protein expression of bile acid receptor CAR
大体时间:2 years
Western blot
2 years
Stomach complaints questionnaire
大体时间:2 years
Questions about stomach complaints
2 years
ReQuest Questionnaire
大体时间:2 years
Reflux evaluation
2 years
Council of Nutrition appetite questionnaire
大体时间:2 years
Questions about appetite
2 years
Bowel complaints questionnaire
大体时间:2 years
Questions about bowel complaints
2 years
Patient health questionnaire
大体时间:2 years
Questions about health
2 years
Anxiety sensitivity index
大体时间:2 years
Questions about anxiety sensitivity
2 years
Visceral sensitivity index
大体时间:2 years
Questions about visceral sensitivity
2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年3月1日

初级完成 (实际的)

2016年11月1日

研究完成 (实际的)

2016年11月1日

研究注册日期

首次提交

2016年12月5日

首先提交符合 QC 标准的

2016年12月23日

首次发布 (估计)

2016年12月26日

研究记录更新

最后更新发布 (估计)

2016年12月26日

上次提交的符合 QC 标准的更新

2016年12月23日

最后验证

2016年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • Bile acid-permeability

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅